← SynDRA
MOLIBRESIB
SynDRA canonical compound SYN0024245 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | BRD3 |
|---|
| Mechanism of action | Bromodomain inhibitor |
|---|
All known targets
- BRD4
- BRD2
- BRD3
- BRDT
- APOA1
Mechanisms of action (all sources)
- BET bromodomain inhibitor
- BRD2 INHIBITOR
- Bromodomain and extra-terminal motif (BET) inhibitor
- BRDT INHIBITOR
- BRD3 INHIBITOR
- BRD4 MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- AAAS
- PSMA6
- PRPF3
- PRPF31
- PRPF4
- PRPF40A
- PRPF6
- PRPF8
- PRR12
- PRTN3
- PSMA4
- PSMD11
- POLR1C
- PSME1
- PSME2
- PSME3
- PSPC1
- PTBP1
- PTGS2
- PUF60
- PUS1
- PWWP2B
- PRPF19
- PRMT1
- PRKDC
- PRKCD
- POLR2A
- POLR2B
- PPIG
- PPIL2
- PPIL4
- PPM1G
- PPP1CA
- PPP1CB
- PPP1R10
- PPP1R12A
- PPP1R9B
- PPP2CA
- PPP2R1A
- PPP6C
Cross-references
Synonyms
- Bet inhibitor gsk525762
- GSK-525762
- GSK-525762A
- GSK525762
- GSK525762A
- I-BET 762
- I-BET-762
- I-BET762
- Bet inhibitor GSK525762
- 5QIO6SRZ2R
- molibresibum
- IBET compound
- I-BET compound
- RefChem:159335
- UNII-5QIO6SRZ2R
- MFCD22417091
- Molibresib (USAN)
- CS-0717
- MOLIBRESIB [USAN]
- GSK-525762A (I-BET 762)
- C22H22ClN5O2
- EAM
- GSK 525762A; I-BET 762
- Molibresib (I-BET-762)
- 2yek
- GSK525762A(Molibresib I-BET762)
- 3p5o
- MOLIBRESIB [INN]
- MOLIBRESIB [WHO-DD]
- GTPL7033
- orb1307159
- SCHEMBL1872390
- SCHEMBL29359178
- CHEBI:95082
- EX-A462
- AAAQFGUYHFJNHI-SFHVURJKSA-N
- GLXC-04299
- GSK2838232A
Look up MOLIBRESIB in the interactive SynDRA portal →